參考文獻(xiàn)：

[1]Dalpiciclib plus endocrine therapy as adjuvant treatment for HR+/HER2–early breast cancer: the randomized, phase 3, DAWNA-A trial.

[2]Jian Zhou, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high-risk of recurrence (CARES-009): a randomized phase 3 trial. 2025 ESMO 1470O.

[3] Wang Z, Fan J, Zhou S, et al. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial. Lancet 2025. Published Online. https://doi.org/10.1016/S0140-6736(25)01720-9.

[4]Wu L, Wang J, Li Q, et al. Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. CA Cancer J Clin. 2026;76(1):e70042. doi:10.3322/caac.70042.

[5]Phase 3 Trial of HRS9531, a GLP-1/GIP Receptor Agonist, in Chinese Adults with Overweight or Obesity. X. Li et al. ObesityWeek? 2025, Annual Meeting of the Obesity Society, Atlanta, GA, November 2025.